Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Show more
WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug...
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.33333333333 | 1.2 | 1.22 | 1.14 | 338025 | 1.16670348 | CS |
4 | -0.04 | -3.33333333333 | 1.2 | 1.22 | 1.14 | 251259 | 1.17313377 | CS |
12 | -0.02 | -1.69491525424 | 1.18 | 1.43 | 1.12 | 554081 | 1.26011579 | CS |
26 | 0 | 0 | 1.16 | 1.43 | 0.9515 | 632762 | 1.21617682 | CS |
52 | -5.48 | -82.5301204819 | 6.64 | 6.98 | 0.5902 | 1888254 | 1.32994254 | CS |
156 | -16.84 | -93.5555555556 | 18 | 19.97 | 0.5902 | 1019971 | 5.35501835 | CS |
260 | -0.12 | -9.375 | 1.28 | 30.375 | 0.5902 | 984504 | 7.78230291 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.